Cohance Lifesciences
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Cohance Lifesciences is currently navigating a challenging operational landscape, with management indicating a cautious recovery in the second half of FY27 following a soft Q1. The company's strategic focus on integrating its nucleic acid business and enhancing ADC capabilities is expected to drive long-term growth, despite near-term headwinds from deferred shipments and high overheads. Vista's financial outlook reflects anticipated revenue contraction and margin pressure, aligning with management's commentary on operational challenges. However, the emphasis on improving plant utilization and executing a robust late-stage pipeline supports a potential rebound in performance. The broader industry context, characterized by increasing demand for CDMO services and a shift in global supply chains, presents opportunities for Cohance to capture market share. Over the next 12-24 months, key opportunities include leveraging the transition away from Chinese suppliers and advancing high-value product offerings, while watchpoints include the execution of the turnaround strategy and the impact of geopolitical factors on costs
Why We Like This Stock
- Management's focus on integrating the nucleic acid business and scaling ADC capabilities is expected to enhance long-term growth prospects
- A robust late-stage pipeline and anticipated restocking orders could support a recovery in revenue in the second half of FY27
- The shift in global supply chains presents significant opportunities for Cohance to capture market share from competitors
Things To Watch Out For
- Revenue is expected to contract due to deferred shipments and high overheads, impacting short-term performance
- Margins are under pressure from rising logistics and raw material costs, exacerbated by geopolitical issues
- Operational challenges in key segments, particularly NJ Bio and AgChem, may hinder immediate recovery efforts
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,051 | 1,198 | 2,269 | 1,871 | 2,023 |
| Profit Before Tax (Cr.) | 361 | 303 | 237 | -118 | 40 |
| PBT Margin | 34.3% | 25.3% | 1044.5% | -6.3% | 2.0% |
| Net Profit (Cr.) | 273 | 226 | 180 | -93 | 26 |
| Earnings Per Share | 7.1 | 6.0 | 5.4 | -2.0 | 0.7 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Goldman Sachs | ▲ Buy | 500 | 06-Aug-2026 |
| ICICI Securities | ▼ Reduce | 365 | 06-Aug-2026 |
| Jeffries | ▼ Underperform | 350 | 06-Aug-2026 |
| Macguire | ▲ Outperform | 1,150 | 06-Aug-2026 |
Company Overview
Show Company Profile
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.